129 related articles for article (PubMed ID: 37929737)
1. Late Relapse in Neuroblastoma: Case Report and Review of the Literature.
Kebudi R; Koc B; Sozmen BO
Curr Pediatr Rev; 2023 Oct; ():. PubMed ID: 37929737
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
3. High-dose
Wakabayashi H; Kayano D; Inaki A; Araki R; Kuroda R; Ikawa Y; Fujiki T; Akatani N; Yamase T; Watanabe S; Hiromasa T; Kunita Y; Mori H; Saito S; Nishimura R; Wada T; Kinuya S
Ann Nucl Med; 2020 Nov; 34(11):840-846. PubMed ID: 32862362
[TBL] [Abstract][Full Text] [Related]
4. The late recurrence of ganglioneuroma 21 years after initial presentation with neuroblastoma.
Okita Y; Narita Y; Yoshida A; Miyakita Y; Ohno M; Saio M; Yoshimi N; Shibui S
Pediatr Hematol Oncol; 2012 Oct; 29(7):647-51. PubMed ID: 22966943
[TBL] [Abstract][Full Text] [Related]
5. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma.
Wieczorek A; Zaniewska-Tekieli A; Ehlert K; Pawinska-Wasikowska K; Balwierz W; Lode H
Front Oncol; 2023; 13():1082771. PubMed ID: 36816982
[TBL] [Abstract][Full Text] [Related]
6. Anatomic patterns of relapse and progression following treatment with
Fishel Ben Kenan R; Polishchuk AL; Hawkins RA; Braunstein SE; Matthay KK; DuBois SG; Haas-Kogan DA
Pediatr Blood Cancer; 2022 Feb; 69(2):e29396. PubMed ID: 34662499
[TBL] [Abstract][Full Text] [Related]
7. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
[TBL] [Abstract][Full Text] [Related]
8. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience.
Olgun N; Cecen E; Ince D; Kizmazoglu D; Baysal B; Onal A; Ozdogan O; Guleryuz H; Cetingoz R; Demiral A; Olguner M; Celik A; Kamer S; Ozer E; Altun Z; Aktas S
Front Oncol; 2022; 12():1041443. PubMed ID: 36620564
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
[TBL] [Abstract][Full Text] [Related]
10. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
Front Immunol; 2021; 12():690467. PubMed ID: 34367149
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Mora J; Castañeda A; Colombo MC; Gorostegui M; Gomez F; Mañe S; Santa-Maria V; Garraus M; Macias N; Perez-Jaume S; Muñoz O; Muñoz JP; Barber I; Suñol M
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809255
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry-based high-activity therapy with
Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
[TBL] [Abstract][Full Text] [Related]
13. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
14. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial.
Klingebiel T; Berthold F; Treuner J; Schwabe D; Fischer M; Feine U; Maul FD; Waters W; Wehinger H; Niethammer D
Med Pediatr Oncol; 1991; 19(2):84-8. PubMed ID: 2011100
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
16. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
17. An Unusual Case of Late Recurrence of MS Neuroblastoma in a Young Adult.
Boulter AC; Watt T
J Pediatr Hematol Oncol; 2023 Jan; 45(1):e124-e125. PubMed ID: 36598966
[TBL] [Abstract][Full Text] [Related]
18. Rhombencephalitis and longitudinal extensive myelitis associated with dinutuximab use in high-risk neuroblastoma.
Atak F; Aydın GB; Öncel İ; Öz S; Oğuz KK
Turk J Pediatr; 2023; 65(3):523-530. PubMed ID: 37395971
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pathologic characteristics and treatment outcomes in children with neuroblastoma at the Kenyatta National Hospital, Nairobi.
Kitonyi GW; Macharia WM; Mwanda OW; Pamnani R
East Afr Med J; 2009 Dec; 86(12 Suppl):S39-46. PubMed ID: 21591508
[TBL] [Abstract][Full Text] [Related]
20. Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients.
Klingebiel T; Feine U; Treuner J; Reuland P; Handgretinger R; Niethammer D
J Nucl Biol Med (1991); 1991; 35(4):216-9. PubMed ID: 1823821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
